Adlai Nortye Group (ANL) News
NASDAQ: ANLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANL news summary
We found 4 recent headlines mentioning Adlai Nortye Group (ANL): 0 in the past week and 0 in the past 30 days, most often from Nasdaq, GlobeNewswire. ANL is making an outsized move today, down 5.63% at $8.55, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data", was published by Nasdaq on Oct 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Adlai Nortye Group headlines
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) - This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.NasdaqABBV, ANL, ARWR, AZN
- Adlai Nortye Partners With Lilly And Merck KGaA To Evaluate AN4035 Combination In Solid Tumors(RTTNews) - Adlai Nortye Group (ANL) has entered into clinical trial collaboration and supply agreements with Eli Lilly and Company (LLY) and Merck KGaA (MKKGY), Darmstadt, Germany to evaluate its…NasdaqANL, LLY
- Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and CetuximabAN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trialGlobeNewswire
- Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.NasdaqANL, TMO